Entries |
Document | Title | Date |
20080207700 | Amino Acid Salts of Rosiglitazone - The invention relates to novel amino acid salts of the racemic or an enantiomeric or tautomeric form of rosiglitazone and to the solvates of said salts. | 08-28-2008 |
20080214624 | Fungicidal Composition Comprising a Pyridylmethylbenzamide Derivative and a Thiazolecarboxamide Derivative - A composition comprising at least a pyridylmethylbenzamide derivative of general formula (1) | 09-04-2008 |
20080227825 | Formulation - This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof. | 09-18-2008 |
20080255206 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases - The present invention relates to the use of one or more retinoid agonists and/or antagonists comprising retinoids with selective Retinoid X Receptor (RXR) agonistic or antagonistic activity alone or in combination with one or more peroxisome proliferator activated receptor (PPAR) ligands for the manufacture of a medicament for the (preferably oral or topical) treatment (this term including prevention/prophylaxis and/or therapy) of one or more manifestations of metabolic syndrome (also known as syndrome X), also called diseases hereinafter, especially from one or more manifestations thereof selected from the group consisting of diabetes type II, obesity, dyslipidemia, hypertension and polyneuropathy, each of which can also be linked with a high risk of cardiovascular diseases. Corresponding methods, the compounds and combinations for use in the treatment of the mentioned diseases and comparable invention embodiments are also described. | 10-16-2008 |
20080262046 | Amidopropoxyphenyl Orexin Receptor Antagonists - The present invention is directed to amidopropoxyphenyl compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 10-23-2008 |
20080262047 | Ppar-Gamma Agonists for Improvement of Cognitive Function in Apoe4 Negative Patients - Disclosed is a method for improving cognitive function in a subject suffering from or susceptible to MCI, Alzheimer's disease or other dementias, which subject is not homozygous for the APOE4 allele, comprising the steps of:
| 10-23-2008 |
20080269300 | Substituted Phenylaminothiazoles and Use Thereof - The present application relates to novel phenylaminothiazole derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders. | 10-30-2008 |
20080280955 | Methods and compositions for screening and treatment of disorders of blood glucose regulation - In one aspect, the invention provides a method of screening and, optionally, treatment of an individual suffering from an insulin resistance disorder by screening an individual in need of treatment for an insulin resistance disorder for one or more genetic variations indicating a predisposition to a response to an insulin sensitizer; and, optionally, administering or not administering an insulin sensitizer to the individual based on the results of the screening. The insulin sensitizer for which the individual is screened and the insulin sensitizer that is administered or not administered may be the same or different. In another aspect, the invention provides methods comprising identifying one or more genetic variations, e.g., one or more single nucleotide polymorphisms, that at least partly differentiate between a subset of a plurality of individuals who experience a response when administered an insulin sensitizer, and a subset of said plurality of individuals who do not experience a response when administered the insulin sensitizer. The invention also provides nucleic acids, polypeptides, antibodies, kits, and business methods associated with these screening and association methods. | 11-13-2008 |
20080293776 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) - Compounds of the formula | 11-27-2008 |
20080293777 | Weight Loss Treatment - The present invention relates to the use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one and other selenium-containing compounds for weight loss. | 11-27-2008 |
20080300282 | Novel process to prepare pioglitazone via several novel intermediates - A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine. | 12-04-2008 |
20080306121 | Bisheterocycle Tandem Compounds Useful as Antiviral Agents, the Uses Thereof and the Compositions Comprising Such Compounds - The present invention provides small molecule compounds of bisheterocycle in tandem having the structural formula of P1-P2, and the use thereof as well as a composition containing the compounds, each of P1 and P2 is an unsaturated 5-member heterocyclic ring having one or two heteroatoms. This compound may effectively inhibit the replication of influenza virus, the DNA replication of hepatitis B virus (HBV), and the formation of HBsAg and HBeAg. These compounds can be used for the preparation of a medicament for viral diseases, and may overcome the limitations of the known nucleosides drugs, including cytotoxicity, the requirement of other drugs having different structures for against the drug-resistant virus variants induced by long-term therapy. The structure of the compounds according to the invention is relatively simple and easy to be prepared. | 12-11-2008 |
20080312291 | Heterocyclic Gaba-b Modulators - The present invention relates to novel thiazole and oxazole derivatives having a positive allosteric GABA | 12-18-2008 |
20080319024 | Rosiglitazone Phosphate and Polymorphic Forms - The present invention relates to 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione phosphate, a novel salt of rosiglitazone and to novel polymorphic forms thereof. The invention is also directed to processes for preparation of rosiglitazone phosphate and its polymorphs. The compounds of the invention are useful for treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof. | 12-25-2008 |
20090030046 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME - Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure | 01-29-2009 |
20090048307 | 5-pyridyl-1, 3-azole compounds, process for producing the same and use there of - An optionally N-oxidized compound represented by the formula: | 02-19-2009 |
20090054493 | THIAZOLE DERIVATIVES AS PPAR DELTA LIGANDS AND THEIR MANUFACTURING PROCESS - The present invention relates to novel thiazole derivative compounds having activity for peroxisome prolif erator-activated receptor δ (PPARδ), as well as their intermediates and synthesis methods thereof. | 02-26-2009 |
20090054494 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE - The present invention comprises N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, their physiologically acceptable salts and functional derivatives that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below, | 02-26-2009 |
20090076093 | DEUTERIUM-ENRICHED ROSIGLITAZONE - The present application describes deuterium-enriched rosiglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090076094 | NOVEL ANTIBACTERIAL COMPOUNDS - This invention relates to a novel purified compound PM181104, of formula: | 03-19-2009 |
20090082405 | DEUTERIUM-ENRICHED PIOGLITAZONE - The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090082406 | Cancer Therapy - This invention relates to a method of regulating the cell cycle and treating cancer with a peroxisome proliferator-activated receptor γ agonist and a mevalonate pathway inhibitor or a mevalonate antagonist. | 03-26-2009 |
20090088457 | Primary Amines as Renin Inhibitors - The invention relates to novel primary amine derivatives and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin. | 04-02-2009 |
20090099238 | USE OF A PPAR-ALPHA AGONIST TO TREAT PATIENTS SUFFERING FROM WEIGHT GAIN ASSOCIATED WITH A PPAR-GAMMA AGONIST TREATMENT - The present invention relates to the use of a pparα agonist to treat patients suffering from weight gain associated with a pparγ agonist treatment. | 04-16-2009 |
20090105308 | Benzoheterocylethylcarboxamide derivatives - The present invention relates to novel benzoheterocyclylethylcarboxamide derivatives of formula (I) in which the substituents are in the description, their process of preparation, their use as fungicides, particularly in the form of fungicidal compositions, methods for the control of phytopathogenic fungi of plants using these compounds or their compositions: | 04-23-2009 |
20090118337 | Methods and compositions for treating inflammation - A method of treating a subject with a cystic fibrosis related disorder includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof. | 05-07-2009 |
20090124667 | Novel Dual-Use Peptidase Inhibitors as Prodrugs for a Therapy of Inflammatory and Other Diseases - Compounds of the general formulae (1) and (2) | 05-14-2009 |
20090137638 | Thiazolidinedione analogues - The present invention relates to thiazolidinedione analogues that are useful for treating hypertension. | 05-28-2009 |
20090143441 | Combination therapies of Thiazolidinedione analogues - The present invention relates to thiazolidinedione analogues that are useful for treating inflammatory disease. | 06-04-2009 |
20090143442 | Thiazolidinedione analogues - The present invention relates to thiazolidinedione analogues that are useful for treating metabolic inflammation mediated diseases such as diabetes. | 06-04-2009 |
20090149507 | METHOD FOR CUSTOMIZED DISPENSING OF VARIABLE DOSE DRUG COMBINATION PRODUCTS FOR INDIVIDUALIZING OF THERAPIES - The method set out herein involves identifying the concentration of each of two or more active therapeutics tailored to treat a particular patient's unique metabolism and one or more diseases, communicating that information to a producer who has multiple fixed or variable concentrations of each active available, where the producer then combines the individual concentrations of each active into single units such as a tablets or pills, and distributes those indirectly or directly to the patient. | 06-11-2009 |
20090149508 | Process for the preparation of substituted phenyl ether compounds - A novel process for the preparation of a compound of the formula (II), which is useful as intermediate compound for the preparation of thiazolidinedione derivatives, such as rosiglitazone, pioglitazone, troglitazone and ciglitazone, is disclosed. | 06-11-2009 |
20090156644 | Use of thiazole derivatives and analogues in the treatment of cancer -
There is provided a use of a compound of formula (I), wherein X, Y, T, W, A | 06-18-2009 |
20090192199 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION - Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor (BDNF). The findings described herein suggest a combinatorial approach for drug therapies, using both positive AMPA receptor modulators and mGluR antagonists. to enhance brain neurotrophism. | 07-30-2009 |
20090203747 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE - The present invention relates to the field of pharmacy, especially the treatment of neurodegenerative diseases. The invention specifically relates to a family of chemical compounds for which a neuroprotective activity has been demonstrated. | 08-13-2009 |
20090221647 | N-(2-THIAZOLYL)-AMIDE DERIVATIVES AS GSK-3 INHIBITORS - The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I), for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus. | 09-03-2009 |
20090253752 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN - The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises;
| 10-08-2009 |
20090253753 | Therapeutic Use of Acylaminothiazole Derivatives - The present invention discloses and claims therapeutic uses of a compound corresponding to the general formula (I): | 10-08-2009 |
20090264474 | SULFONAMIDES AS TRPM8 MODULATORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: | 10-22-2009 |
20090291985 | METHODS AND KIT FOR EARLY DETECTION OF ACUTE CORONARY SYNDROME AND PREDICTION OF ADVERSE CARDIAC EVENTS - The invention provides methods for early diagnosis or detection of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS) in a human subject at the time of presentation of the chest pain. The method includes analyzing a test sample of the biological fluid for amount of catalytic iron and detecting acute coronary syndrome in the human subject. | 11-26-2009 |
20090291986 | COMPOSITION AND METHOD OF TREATING FACIAL SKIN DEFECT - This invention relates to a subcutaneous deliverable composition containing an agonist of the peroxisome proliferator-activated receptor-gamma, and a method for treating facial skin defects in a mammalian subject using the subcutaneous deliverable composition. | 11-26-2009 |
20090306148 | Use of Thiazolidinediones for the Partial Inhibition of Androgen Binding to Aromatase - A method for the treatment or prophylaxis of a disorder, wherein the disorder is affected by estrogen, comprising partially inhibiting aromatase activity or interfering with the binding of androgen to aromatase by administering a therapeutically effective amount of a thiazolidinedione to the patient. The use of rosiglitazone or pioglitazone to partially inhibit the binding of androgen to aromatase by at least 20% is preferred. | 12-10-2009 |
20100022600 | METHODS AND COMPOSITIONS FOR TREATING CENTRAL NERVOUS SYSTEM TUMORS - A method of treating a central nervous system tumor in a subject includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof to the tumor in the subject. | 01-28-2010 |
20100029722 | ORGANIC COMPOUNDS - The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 02-04-2010 |
20100041710 | PENETRATION ENHANCER FOR INSECTICIDES - Methods for enhancing penetration of agrochemical active substances through the cuticle of a plant are disclosed. Also disclosed are compositions comprising at least one penetration enhancer. | 02-18-2010 |
20100041711 | Urea Glucokinase Activators - This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such. | 02-18-2010 |
20100048641 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases - The present invention relates to the use of A1 and/or dual A1/A2 | 02-25-2010 |
20100056583 | Polymorphic forms of rosiglitazone hydrobromide and processes for their preparation - The present invention provides crystalline forms of Rosiglitazone hydrobromide, methods of their preparation, as well as pharmaceutical compositions comprising these crystalline forms. | 03-04-2010 |
20100063108 | Pyridin-4-yl derivatives as immunomodulating agents - The invention relates to pyridine derivatives of Formula (I) wherein A, R | 03-11-2010 |
20100063109 | THIADIAZOLIDINONE DERIVATIVES - The present invention relates to compounds of the formulae herein, their acceptable salts, solvates, hydrates and polymorphs thereof. The compounds of this invention are useful in treatment of disease, particularly leukemia. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating disease, disorders, or symptoms thereof in a subject. | 03-11-2010 |
20100081694 | COMPOSITION COMPRISING AT LEAST ONE PPAR AGONIST AND A LIPID COMPONENT - The present invention relates to compositions comprising at least one peroxisome proliferator-activated receptor (PPAR) agonist and a lipid component and to pharmaceutical ingredients comprising said ingredients. Such compositions are particularly suitable for the prophylaxis and/or the treatment of diseases such as diabetes, obesity and hypertriglyceridemia. | 04-01-2010 |
20100081695 | 2-N-{5-[ [4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate - Disclosed is an isolated compound of the formula: | 04-01-2010 |
20100093809 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS - A compound having a structure | 04-15-2010 |
20100099718 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME - The present invention provides an antifungal agent that has excellent antifungal action, and is also excellent in terms of its properties, safety, and metabolic stability. The present invention discloses a compound represented by the following formula I or a salt thereof, and an antifungal agent comprising the compound or the salt: | 04-22-2010 |
20100113531 | THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS - The invention relates to novel thiazolidine derivatives of the formula (I) wherein A and R | 05-06-2010 |
20100113532 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF - A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or (II): | 05-06-2010 |
20100120868 | Process For Preparing Solid Dosage Forms of Rosiglitazone Maleate - The invention relates to a process for preparing a solid pharmaceutical composition rosiglitazone maleate, comprising the step of adsorption of rosiglitazone maleate onto carrier particles (C) during a dry mixing process. | 05-13-2010 |
20100152249 | COMPOSITONS AND METHOD FOR TREATMENT OF MOOD AND COGNITIVE IMPAIRMENTS - Compositions, manufacture, and methods for diagnosis and treatment of subjects exhibiting mood disorders and/or being at risk of cognitive impairment. | 06-17-2010 |
20100168183 | SUBSITUTED CYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE - The present invention provides a substituted cyclic compound of the following general formula I or II: | 07-01-2010 |
20100168184 | SMALL MOLECULE BCL-X1/BCL-2 BINDING INHIBITORS - Bcl-xL/Bcl-2 binding inhibitors useful in the treatment of unwanted proliferating cells, including cancers and precancers, in subjects in need of such treatment. Also provided are methods of treating a subject having unwanted proliferating cells comprising administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject in need of such treatment. Also provided are methods of preventing the proliferation of unwanted proliferating cells, such as cancers and precancers, in a subject comprising the step of administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject at risk of developing a condition characterized by unwanted proliferating cells. | 07-01-2010 |
20100168185 | Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi - The present invention relates to the use of known 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi in plants and parts of plants, and also to methods for controlling phytopathogenic fungi in plants and parts of plants in crop protection, and also to crop protection compositions comprising these 5-pyridin-4-yl-1,3-thiazoles. | 07-01-2010 |
20100173950 | HETEROARYL (SUBSTITUTED)ALKYL N-SUBSTITUTED SULFOXIMINES AS INSECTICIDES - N-Substituted heteroaryl (substituted)alkyl sulfoximines are effective at controlling insects. | 07-08-2010 |
20100184810 | METHODS AND COMPOSITIONS RELATED TO RIBOSWITCHES THAT CONTROL ALTERNATIVE SPLICING - Disclosed are methods and compositions related to riboswitches that control alternative splicing. | 07-22-2010 |
20100240709 | Sulfoximine Derivatives as p38 MAP Kinase Inhibitors - The present invention relates to novel compounds of general formula (I), their regioisomers, tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (I), their regioisomers, their tautomeric forms, their pharmaceutically acceptable salts pharmaceutical compositions containing them, and novel intermediates involved in their synthesis. | 09-23-2010 |
20100249195 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formula (I): | 09-30-2010 |
20100261761 | Novel Sulfonylpyrroles - Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors. | 10-14-2010 |
20100280078 | 1-(Azolin-2-yl)amino-1,2-diphenylethane compounds for combating animal pests - The present invention relates to 1-(azolin-2-yl)amino-1,2-diphenylethane compounds of the formula I and to their salts which are useful for combating animal pests. The invention also relates to a method for controlling animal pests by using these compounds, to seed and to an agricultural and veterinary composition comprising said compounds. | 11-04-2010 |
20100280079 | 0NOVEL, 1,2,4-THIADIAZOLIUM DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS - The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II diabetes, Syndrome X, diabetic retinopathy, spinal cord injury, nerve injury, acute neurodegenerative disorders, chronic neurodegenerative disorders, plexopathies, male erectile dysfunction, dry eyes, acne, dry skin, aged skin, seborrheic dermatitis, rosacea, excessive ear wax, meibomian gland disorder, pseudofolliculitis, yeast infections, dandruff, hidradenitis suppurativa, ocular rosacea and eccrine gland disorder. | 11-04-2010 |
20100280080 | Medicaments - Methods of prevention or treatment of renal diseases or conditions associated with abnormal ion flux, in particular autosomal dominant polycystic kidney disease, with a modulator of human peroxisome proliferator activated receptor gamma. | 11-04-2010 |
20100292277 | COMBINATION TREATMENT OF METABOLIC DISORDERS - Various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis can be treated with a combination of a direct PPAR-gamma agonist and a Compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) Three of R | 11-18-2010 |
20100292278 | Methods of treating vascular disease and injury - The present invention provides a method of treating a vascular disease or injury in an individual in need of such treatment, comprising the step of administering a compound or composition that down-regulates or decreases the activity of microRNA-29 in the individual. Also provided is a method of down-regulating or decreasing the activity of microRNA-29 in an individual in need of such treatment, comprising the step of administering a PPAR-γ agonist compound or PPAR-γ agonist containing composition that down-regulates or decreases the activity of microRNA-29 in the individual. Further provided is a method of treating a vascular disease or injury in an individual in need of such treatment, comprising the step of administering a microRNA-29 antagonist that down-regulates or decreases the activity of microRNA-29 in said individual. | 11-18-2010 |
20100298385 | PROTEIN KINASE INHIBITORS USEFUL FOR TREATMENT OF CANCERS - This invention relates to protein kinase inhibitors useful for treating cancers. The present protein kinase inhibitors are those having the structures of the following formula or pharmaceutically acceptable salts thereof. | 11-25-2010 |
20100305164 | 5-(4-METHANESULFONYL-PHENYL)-THIAZOLE DERIVATIVES FOR THE TREATMENT OF ACUTE AND CHRONIC INFLAMMATORY DISEASES - A compound of formula (I): | 12-02-2010 |
20100324096 | Whitening Agent And Skin External Preparation - The present invention provides a compound having an excellent inhibitory action on melanin production and being useful as a whitening agent, and a skin external preparation containing the compound. The whitening agent of the present invention comprises, as an active ingredient, a heterocyclic compound represented by formula (1) or a pharmacologically acceptable salt thereof: | 12-23-2010 |
20100331373 | DRUG-CONTAINING NANOPARTICLES - The present invention relates to nanoparticles containing pioglitazone or a salt thereof and a biocompatible polymer, a pharmaceutical preparation containing the nanoparticles for the prophylaxis or treatment of arteriosclerotic diseases, and a stent carrying the nanoparticles. Using the nanoparticles of the present invention, rupture of arteriosclerotic plaque can be suppressed, and they are useful for the prophylaxis or treatment of arteriosclerotic diseases. | 12-30-2010 |
20110021576 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES - A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine. | 01-27-2011 |
20110034518 | Pharmaceutical composition - Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes. | 02-10-2011 |
20110046187 | ASSESSING CONGESTIVE HEART RISK IN PATIENTS TREATED OR POTENTIALLY TO BE TREATED WITH A PEROXISOME-PROLIFERATOR-ACTIVATOR-RECEPTOR-GAMMA AGONIST OR A THIAZOLIDINEDIONE - Methods are provided for assessing a patient being treated with a peroxisome-proliferator-activator-receptor-γ (PPAR-γ) agonist or a thiazolidinedione (TZD), or having a condition treatable with a peroxisome-proliferator-activator-receptor-γagonist or a thiazolidinedione. Methods include measuring a galectin-3 concentration or a change in a galectin-3 concentration in a body fluid of a patient being treated with a peroxisome-proliferator-activator-receptor-γ agonist or a thiazolidinedione. A comparison to galectin-3 levels or changes in comparable patients provides information indicative of congestive heart risk. | 02-24-2011 |
20110053986 | RESPIRATORY DISEASE TREATMENT - There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit. | 03-03-2011 |
20110060014 | Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents - The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases. | 03-10-2011 |
20110065756 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY-RELATED DISEASES - The invention relates to methods, compositions, and kits for combination therapy of diabetes and diabetes-related diseases and conditions (e.g., obesity). The invention finds use in patients suffering from or at risk for diabetes or diabetes-related conditions generally, and in patients also suffering from or at risk for fluid retention (e.g., edema, congestive heart failure) and/or in need of synergistic anti-inflammatory, anti-hypertensive, and anti-diabetic effect. | 03-17-2011 |
20110071196 | Compounds Which Selectively Modulate The CB2 Receptor - Compounds of formula (I) | 03-24-2011 |
20110098323 | INHIBITORS OF BACTERIAL BIOFILM FORMATION - Organic compounds are described for use in inhibiting or preventing formation of bacterial biofilms. | 04-28-2011 |
20110144165 | PRODRUG COMPOUNDS USEFUL AS CANNABINOID LIGANDS - The present invention provides for compounds of formula (I) | 06-16-2011 |
20110166185 | DISEASE RISK FACTORS AND METHODS OF USE - Provided herein are genetic variants associated with development of a condition of interest (e.g., Alzheimer's disease). Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene. | 07-07-2011 |
20110184027 | TISSUE SELECTIVE STEAROYL-COA DESATURASE 1 INHIBITORS AND CELL BASED SCREENING ASSAY FOR THEIR IDENTIFICATION - The present invention provides a method of treating a disorder treatable by administering a therapeutically effective amount of a tissue selective Stearoyl-CoA Desaturase 1 (SCD-1) modulator to a subject. In one embodiment, the present invention provides a method of treating a disorder treatable by administering a pharmaceutically effective amount of a tissue selective SCD-1 inhibitor to a subject. The invention also provides whole cell based screening assays to identify agents that selectively modulate the activity of SCD-1. This invention further provides whole cell based screening assays to identify agents that differentially inhibit SCD in different body tissues. | 07-28-2011 |
20110201651 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF - This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders. | 08-18-2011 |
20110213000 | N-(2-THIAZOLYL)-AMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES AND CARDIOVASCULAR DISEASES - The invention relates to the use of a compound of formula (I): | 09-01-2011 |
20110224263 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals - The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. | 09-15-2011 |
20110224264 | MEDICAMENTS - Methods of prevention or treatment of renal diseases or conditions associated with abnormal ion flux, in particular autosomal dominant polycystic kidney disease, with a modulator of human peroxisome proliferator activated receptor gamma. | 09-15-2011 |
20110230526 | Thiazolyl Mglur5 Antagonists and Methods for Their Use - The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts. | 09-22-2011 |
20110237630 | CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF - A compound represented by the formula (I) | 09-29-2011 |
20110294858 | SUBSTITUTED 6-METHYLNICOTINAMIDES AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS - In one aspect, the invention relates to substituted 6-methylnicotinamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 12-01-2011 |
20120015982 | Thiazolidinedione analogues - The present invention relates to thiazolidinedione analogues that are useful for treating metabolic inflammation mediated diseases such as diabetes. | 01-19-2012 |
20120022113 | METHODS FOR SUPPRESSING TIPDC TRAFFICKING OR ACCUMULATION AND PREVENTING HYPERCYTOKINEMIA - The present invention features methods for preventing or ameliorating hypercytokinemia or preventing lethality-associated with infection by highly pathogenic strains of influenza virus by suppressing TNF-α/Inducible nitric oxide synthase-Producing dendritic cell trafficking or accumulation. In particular embodiments, the expression MyD88, CCR2, MCP-I or MCP-3 is targeted. | 01-26-2012 |
20120029028 | Compositions and methods for treating hyperlipidemias - The present invention is directed to a composition and method for the treatment of hyperlipidemias by targeting Microsomal triglyceride transfer protein (MTP). In particular, the present invention is directed to a combination of at least one MTP inhibitor and at least one lipid-lowering agent, both in an amount effective to treat hyperlipidemias. | 02-02-2012 |
20120029029 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS - The present invention is directed to substituted thiazol-2-ylamine derivatives and pharmaceutically acceptable salts thereof that inhibit 11βHSD1 and that may be useful in the treatment of diseases in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable. | 02-02-2012 |
20120029030 | METHOD FOR CUSTOMIZED DISPENSING OF VARIABLE DOSE DRUG COMBINATION PRODUCTS FOR INDIVIDUALIZING OF THERAPIES - Generally the method involves identifying the concentration of each of two or more active therapeutics tailored to treat a particular patient's unique metabolism and one or more diseases, communicating that information to a producer who has multiple fixed or variable concentrations of each active available, where the producer then combines the individual concentrations of each active into single units such as a tablets or pills, and distributes those indirectly or directly to the patient. | 02-02-2012 |
20120077847 | ALPHA-KETOAMIDE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS - The present invention is directed to α-ketoamide derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by endothelial lipase, for example, cardiovascular disorders. | 03-29-2012 |
20120077848 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES - A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine. | 03-29-2012 |
20120095058 | Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses - The present invention discloses compounds and pharmaceutical compositions which are highly effective at inhibiting the accumulation of spliced and unspliced viral transcripts and their utilization for viral protein synthesis at cellular ribosomes, and at inhibiting the formation of the hypusine residue in cellular eIF-5A precursor proteins, the cellular cofactors that render spliced and unspliced viral transcripts translatable at the ribosomes of infectled cells. The invention further relates to methods of using such compounds and pharmaceutical compositions therefrom for inhibiting or preventing viral protein synthesis. Such inhibition cause a dose-dependent release from the virally induced arrest of the otherwise genetically preprogrammed apoptosis of virally infected cells, and in consequence, triggers their apoptotic ablation and the eradication of the chronic infection-mediating provirus integrated into their genome. | 04-19-2012 |
20120095059 | Compositions and Methods for Treating Type II Diabetes and Related Disorders - The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation, as convenient therapy to reduce glucose levels in blood, preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments, the invention provides orally administerable combination pharmaceutical formulations, comprising at least one insulin sensitizer (e.g., a glitazone such as pioglitazone or rosiglitazone), at least one sulfonylurea (e.g., glimepiride), and at least one biguanide (e.g., metformin or a pharmaceutically acceptable salt or ester thereof, such as metformin HCl). The present invention also provides methods of treating type II diabetes and related disorders in a mammal, suitably a human, by administering to a mammal in need thereof one or more of the compositions of the present invention. | 04-19-2012 |
20120101134 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS - 5-membered heteroaryl derivatives of formula (I) or salts thereof, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed. | 04-26-2012 |
20120115912 | RXR AGONIST COMPOUNDS AND METHODS - A method of treating a PPARγ and/or RXR related disease or disorder in a subject includes adminstering to the subject an RXR agonist alone or in combination with a PPARγ agonist. | 05-10-2012 |
20120142740 | NOVEL ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 06-07-2012 |
20120149734 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES - The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 06-14-2012 |
20120165374 | AGENTS FOR CONTROLLING PLANT PESTS - The present invention relates to compositions for controlling plant pests containing the compound of the formula (I) | 06-28-2012 |
20120184584 | METHODS AND DRUG PRODUCTS FOR TREATING ALZHEIMER'S DISEASE - Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype. | 07-19-2012 |
20120232118 | SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME - Potent and selective ligands for the dopamine 3 (D | 09-13-2012 |
20120245205 | COMPOSITIONS AND METHODS FOR INHIBITING HAIR GROWTH - A method for inhibiting hair growth in mammals using compositions containing FP receptor antagonists (e.g., prostaglandin F analogs that are block activation of the FP receptor). The compositions can be applied topically to the skin and/or hair. The compositions can arrest hirsutism or hypertrichosis, reverse hirsutism and hypertrichosis, and further prevent hair growth. These compositions can also be used to protect hair from chemical or radiation-induced alopecia or hair loss. These compositions can also be used to inhibit pigmentation of the hair or skin. | 09-27-2012 |
20120258988 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR DIABETES - A therapeutic or prophylactic agent for diabetes includes a thiazolidine derivative as a PPAR-γ agonist as an effective component which exhibits a reduced side effect of the PPAR-γ agonist. The therapeutic or prophylactic agent for diabetes includes a particular IP agonist such as beraprost sodium (BPS), and a thiazolidine derivative such as pioglitazone or a pharmaceutically acceptable salt thereof. Since the therapeutic or prophylactic agent exhibits a sufficiently effective hypoglycemic action without being accompanied by side effects characteristic to PPAR-γ agonists, the agent is useful as a highly safe and effective therapeutic or prophylactic agent for diabetes. | 10-11-2012 |
20120264786 | USE OF THIAZOLIDINEDIONES FOR THE PARTIAL INHIBITION OF ANDROGEN BINDING TO AROMATASE - A method for the treatment or prophylaxis of a disorder, wherein the disorder is affected by estrogen, comprising partially inhibiting aromatase activity or interfering with the binding of androgen to aromatase by administering a therapeutically effective amount of a thiazolidinedione to the patient. The use of rosiglitazone or pioglitazone to partially inhibit the binding of androgen to aromatase by at least 20% is preferred. | 10-18-2012 |
20120264787 | Respiratory Disease Treatment - There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit. | 10-18-2012 |
20120309795 | HETEROCYCLIC INHIBITORS OF NECROPTOSIS - The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role. | 12-06-2012 |
20130040996 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF - Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL). | 02-14-2013 |
20130045995 | FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES - The present invention relates to hydroximoyl-heterocycle derivatives of formula (I) | 02-21-2013 |
20130102637 | PEST CONTROL AGENT - Provided is a novel pest control agent using at least one imino derivative represented by the following chemical formula (I): | 04-25-2013 |
20130143930 | ACTIVATION OF AMP-PROTEIN ACTIVATED KINASE BY OXALOACETATE COMPOUNDS - The present invention relates to oxaloacetate compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, Alzheimer's disease, and cancer. | 06-06-2013 |
20130158077 | PHARMACEUTICAL COMPOSITIONS - The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis. | 06-20-2013 |
20130158078 | Heterocyclic Sulfone MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction - Heterocyclic sulfone compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction. | 06-20-2013 |
20130172391 | PHARMACEUTICAL COMPOSITIONS - The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis. | 07-04-2013 |
20130184312 | Tetomilast Polymorphs - The present invention provides a tetomilast crystal that is industrially easily produced in a large volume. (1) a tetomilast hydrate crystal having a power X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in FIG. | 07-18-2013 |
20130203820 | Thiazolidinedione analogues - The present invention relates to thiazolidinedione analogues that are useful for treating metabolic inflammation mediated diseases such as diabetes. | 08-08-2013 |
20130203821 | Pyridine Compounds for Controlling Invertebrate Pests II - The present invention relates to novel pyridine compounds of the formulae I and II, to their salts, to their tautomers, to their N-oxides, and to the salts of these N-oxides or tautomers. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests. The invention also relates to a method for controlling in-vertebrate pests by using these compounds. The invention further relates to plant propagation material and to agricultural compositions comprising said compounds. | 08-08-2013 |
20130274295 | PIOGLITAZONE FOR USE IN THE TREATMENT OF ADRENOLEUKODYSTROPHY - The present invention is directed to pioglitazone, or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition comprising pioglitazone, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, for use in the treatment and/or prevention of an adrenoleukodystrophy. | 10-17-2013 |
20130281493 | Method for Treating Cancer Harboring a p53 Mutation - A method for determining if a subject with cancer or precancerous lesions or a benign tumor, will respond to treatment with an inhibitor selected from the group comprising an inhibitor of one or more enzymes in the mevalonate pathway, an inhibitor of geranylgeranyl transferase, an inhibitor of farnesyl transferase or an inhibitor of squalene synthase, by (i) obtaining a sample of the cancer cells, precancerous cells or benign tumor cells from the subject, (ii) assaying the cells in the sample for the presence of a mutated p53 gene or a mutant form of p53 protein or a biologically active fragment thereof, and (iii) if the cells have the mutated p53 gene or mutant form of the p53 protein, then determining that the subject will respond to treatment with the inhibitor or combinations thereof. Some embodiments are directed to treatment with the inhibitors. | 10-24-2013 |
20130303573 | Brown Adipocyte Progenitors in Human Skeletal Muscle - Brown adipose tissue (“BAT”) progenitor cells and methods for identifying BAT progenitor cells in a population of cells are provided. Methods are also provided for inducing differentiation of BAT progenitor cells into differentiated brown adipocytes, inducing expression or increased activity levels of BAT uncoupling protein-1 (“UCP1”), and for identifying agents capable of inducing differentiation of BAT progenitor cells into brown adipocytes and/or inducing expression or increased activity levels of UCP1. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for treatment of or the making of medicaments for the treatment of metabolic diseases or conditions in a patient such as obesity, overweight, impaired glucose tolerance, insulin-resistance, type 2 diabetes, dyslipidemia, hypertension, cardiovascular diseases, metabolic syndrome, and the like. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for prevention of hypothermia. | 11-14-2013 |
20130317070 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS - The invention provides for the use of antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit anti-mycobacteria activity, including the mycobacterium causing tuberculosis. Multiple compounds were synthesized and screened for anti-tuberculosis activity. Disclosed herein are a series of compounds with anti-tuberculosis activity, including six leads that completely inhibited bacterial growth at 5 micrograms per ml or less. Three of these compounds were tested to determine MIC and these ranged between 1 and 4 micrograms per ml against both drug susceptible | 11-28-2013 |
20140005232 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | 01-02-2014 |
20140088154 | NOVEL INSECTICIDES - Compounds of formula I | 03-27-2014 |
20140113937 | Tetomilast Polymorphs - The present invention provides a tetomilast crystal that is industrially easily produced in a large volume. (1) a tetomilast hydrate crystal having a power X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in FIG. | 04-24-2014 |
20140142145 | COMBINATIONS COMPRISING A DIPEPTIDYLPEPTIDASE - IV INHIBITOR - The present invention is directed to a combination comprising a dipeptidylpeptidase-IV (DPP-IV) inhibitor in free or pharmaceutically acceptable form, and at least one further antidiabetic compound or the pharmaceutically acceptable salt of such a compound, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by DPP-IV, such as impaired glucose tolerance, conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis, and preferably diabetes, especially type 2 diabetes mellitus. | 05-22-2014 |
20140148488 | Compositions and Methods for Modulating Metabolic Pathways - Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine. | 05-29-2014 |
20140171470 | POLYMORPHS OF (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-(-AMIDE - The present invention relates to specific solid forms of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide, and its solvates. The present invention further relates to processes for preparing said solid forms, pharmaceutical compositions comprising said solid forms, and methods of using said solid forms and pharmaceutical compositions to treat disease. | 06-19-2014 |
20140179743 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) - A compound, having the formula A-1: | 06-26-2014 |
20140179744 | SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS - A pharmaceutical combination comprising (a) the phosphatidylinositol 3-kinase (PI3K) inhibitor compound (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination. | 06-26-2014 |
20140194474 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF - Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL). | 07-10-2014 |
20140221433 | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl- )phenyl]acetamide mesylate monohydrate - The present invention relates to an improved and shortened synthesis of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide and the mesylate monohydrate salt thereof by using boronic acid derivatives or borolane reagents while avoiding toxic organic tin compounds and to the mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions. | 08-07-2014 |
20140235676 | RXR AGONIST COMPOUNDS AND METHODS - A method of treating a psychiatric or cognitive developmental disorder in a subject, includes administering to the subject a therapeutically effective amount of at least one RXR agonist. | 08-21-2014 |
20140243377 | DEUTERIUM-ENRICHED PIOGLITAZONE - The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 08-28-2014 |
20140256772 | PHARMACEUTICAL COMPOSITIONS THAT INHIBIT DISPROPORTIONATION - Pharmaceutical formulations comprising solid pharmaceutically acceptable organic acids, such as maleic acid or tartaric acid, that inhibit the disproportionation of pharmaceutically acceptable acid salts of active pharmaceutical ingredients, and methods of manufacturing such pharmaceutical compositions. The pharmaceutically acceptable acid salt of the active pharmaceutical ingredient has a pKa of less than about 6.0, and wherein the solid pharmaceutically acceptable organic acid has a pKa of less than about 4.0 and an aqueous solubility in the range of about 500 to about 2000 milligrams per milliliter. A pharmaceutical formulation comprising a pharmaceutical acceptable acid salt of pioglitazone, a solid pharmaceutically acceptable organic acid selected from the group consisting of maleic acid or tartaric acid, and an excipient that promotes disproportionation, wherein the ratio by weight of the solid pharmaceutically acceptable organic acid to excipient is from about 1:6 to about 1:1. | 09-11-2014 |
20140275178 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS - Provided herein are compounds of the formula (I): | 09-18-2014 |
20140275179 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES - Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: | 09-18-2014 |
20140275180 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME - The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same. | 09-18-2014 |
20140296299 | METHODS AND COMPOSITIONS FOR LOCALLY INCREASING BODY FAT - Provided are methods for increasing fat locally in a body of a subject in need thereof comprising percutaneously administering to the subcutaneous fat of the subject a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, optionally delivered as a composition comprising a pharmaceutically acceptable carrier, as described herein. In certain embodiments, the pharmaceutically acceptable carrier comprises a percutaneous carrier, as described herein. Further provided are compositions comprising a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, for use according to the invention. | 10-02-2014 |
20140303213 | Compositions and Methods for the Treatment of Metabolic Disorders - The present invention relates to the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. Also provided are methods for the treatment and/or prevention of one or more metabolic disorders, for example, obesity or diabetes, utilizing fatostatin A and/or a derivative and/or analog thereof and/or the A-B-C tripartite compounds. | 10-09-2014 |
20140323525 | Fungicidal Active Substance Combinations Containing Trifloxystrobin - What are described are novel active compound combinations comprising a known oxime ether derivative (trifloxystrobin) and imidacloprid, which combinations are highly suitable for controlling phytopathogenic fungi and insects. | 10-30-2014 |
20140357675 | Substituted Phenylazole Derivatives - Compounds are provided having an excellent hypoglycemic effect and β cell- or pancreas-protecting effects, or pharmaceutically acceptable salts thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause hyperglycemia due to abnormal glucose metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed. | 12-04-2014 |
20140364459 | CO-ADMINISTRATION OF ROSIGLITAZONE AND EICOSAPENTAENOIC ACID OR A DERIVATIVE THEREOF - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on rosiglitazone therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 12-11-2014 |
20140364460 | USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION - Fatostatin, a recently described inhibitor of SREBP activation, significantly reduces the level of mutant p53 binding to the HMG-CoA reductase gene promoter. Further, fatostatin treatment had a dramatic effect on normalizing the abnormal 3D morphology of 3 strains of breast cancer cells: MDA-468 cells, MDA-231 cells, and SKBR3 cells. The results show a functional interaction with SREBPs as being critical for mutant p53-mediated upregulation of the mevalonate pathway genes. At a clinical level, inhibition of the mevalonate pathway, either alone or in combination with other therapies, offers a novel, safe and much needed therapeutic option for tumors bearing mutant p53. | 12-11-2014 |
20140364461 | METHOD OF TREATING DERMATOLOGICAL DISORDERS - A method of treating a dermatological disorder in a subject includes the step of administering a therapeutically effective amount of at least one PPARγ agonist or derivative thereof to the subject. | 12-11-2014 |
20140364462 | PYRIDINE DERIVATIVES - The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer. | 12-11-2014 |
20140371276 | TRPM8 ANTAGONISTS - The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exhacerbated respiratory disorders and urological disorders. | 12-18-2014 |
20140378510 | SMALL MOLECULE ACTIVATORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS AND METHODS OF USE - Provided herein are small molecule activators of calcium-activated chloride channels. These small molecules may be used for treatment of diseases and disorders that are treatable by activating calcium-activated chloride channels, such as cystic fibrosis, disorders related to salivary gland dysfunction (for example, Sjogren's syndrome and dysfunction following radiation injury), dry eye syndrome, and intestinal hypomotility. | 12-25-2014 |
20140378511 | PYRIDINE DERIVATIVES - The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer. | 12-25-2014 |
20150045396 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR GIANT CELL TUMORS OCCURRING IN BONE AND SOFT TISSUE OR FOR CHONDROSARCOMA - The present invention provides a prophylactic or therapeutic agent for giant cell tumors occurring in a bone and soft tissue or for chondrosarcoma, which comprises a non-steroidal anti-inflammatory agent or thiazolidine derivative as an active ingredient, and the like | 02-12-2015 |
20150051252 | COMPOUNDS FOR USE IN THE TREATMENT OF NEUROBLASTOMA, EWING'S SARCOMA OR RHABDOMYOSARCOMA - The present invention relates to a method of treating cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma comprising administering a therapeutically effective amount of a compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof to a subject, preferably a human, in need thereof; to use of the compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for use in the treatment of cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma; and to use of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the treatment of cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma. | 02-19-2015 |
20150073022 | DISEASE RISK FACTORS AND METHODS OF USE - Provided herein are genetic variants associated with development of a condition of interest (e.g., Alzheimer's disease). Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene. | 03-12-2015 |
20150087678 | METHODS OF TREATING LACTOSE INTOLERANCE - Disclosed herein are methods for treating lactose intolerance, including compounds that may be specific or modulate PPARγ receptors. | 03-26-2015 |
20150111927 | PHARMACEUTICAL DIAGNOSTIC - The present invention relates to selective cancer treatment regimes based on assaying for the presence or absence of a glutamine or a nucleic acid that encodes glutamine at position 859 of the catalytic p110α subunit of PI3K; methods for producing a transmittable form of information for predicting the responsiveness of patient to (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or a pharmaceutically acceptable salt thereof; and a kit thereof. | 04-23-2015 |
20150133507 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS - The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis. | 05-14-2015 |
20150313825 | METHODS AND COMPOSITIONS FOR LOCALLY INCREASING BODY FAT - Provided are methods for increasing fat locally in a body of a subject in need thereof comprising percutaneously administering to the subcutaneous fat of the subject a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, optionally delivered as a composition comprising a pharmaceutically acceptable carrier, as described herein. In certain embodiments, the pharmaceutically acceptable carrier comprises a percutaneous carrier, as described herein. Further provided are compositions comprising a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, for use according to the invention. | 11-05-2015 |
20150315160 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 - The invention is concerned with a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament. | 11-05-2015 |
20150328198 | METHODS OF TREATING METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) USING PPAR-GAMMA AGONISTS - The present invention relates to methods of preventing or treating a | 11-19-2015 |
20150342914 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS - Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine. | 12-03-2015 |
20150352095 | Tetomilast Polymorphs - The present invention provides a tetomilast crystal that is industrially easily produced in a large volume. (1) a tetomilast hydrate crystal having a power X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in FIG. | 12-10-2015 |
20150368214 | SCHIFF BASES OF THIAZOLES: A NEW CLASS OF UREASES INHIBITORS - One embodiment of the invention relates to treating diseases associated with increased urease enzyme activity comprising administering an effective amount of a compound selected from a group consisting of 28 thiazoles Schiff bases. Kinetic studies were performed on ten (10) of the most active compounds. | 12-24-2015 |
20160000769 | METHODS AND DRUG PRODUCTS FOR TREATING ALZHEIMER'S DISEASE - Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype. | 01-07-2016 |
20160016944 | FUNGICIDAL 3--HETEROCYCLE DERIVATIVES - The present invention provides 3-{phenyl[(heterocyclylmethoxy)imino]methyl}-heterocyclyl derivatives of formula (I) | 01-21-2016 |
20160058741 | Thiadiazolidinone Derivatives - The present invention relates to compounds of the formulae herein, their acceptable salts, solvates, hydrates and polymorphs thereof. The compounds of this invention are useful in treatment of disease, particularly leukemia. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating disease, disorders, or symptoms thereof in a subject. | 03-03-2016 |
20160081993 | SUBSTITUTED PHENYLAZOLE DERIVATIVE - Compounds are provided having an excellent hypoglycemic effect and β cell- or pancreas-protecting effects, or pharmaceutically acceptable salts thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause hyperglycemia due to abnormal glucose metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed. | 03-24-2016 |
20160113915 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS - Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine. | 04-28-2016 |
20160128993 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER - According to the invention there is provided a compound of formula (I) wherein: A represents C(═N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(═N—W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(—NH—W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CR | 05-12-2016 |
20160128994 | PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES - Compositions and methods are described herein for the treatment of cystic diseases using PPARγ modulators. In particular, compositions and methods are described herein for the treatment of cystic diseases using low doses of PPARγ modulators. | 05-12-2016 |
20160130241 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS - Provided herein are compounds of the formula (I): | 05-12-2016 |
20160143283 | SUSPENSION CONCENTRATE COMPOSITION COMPRISING ISOTHIAZOLINE INSECTICIDE AND ACTIVATED CHARCOAL - Subject matter of the present invention is a suspension concentrate composition comprising an a) isothiazoline insecticide and b) activated charcoal, wherein the composition is substantially free of a non-polar solvent. The invention further relates to a process for the preparation of said composition; a suspension obtainable by mixing water, an isothiazoline insecticide and activated charcoal; and to a method for controlling undesired attack by insects or mites, where the suspension concentrate composition or the suspension is allowed to act on the respective pests, their environment or on the crop plants to be protected from the respective pests. | 05-26-2016 |
20160151344 | COMPOUNDS FOR USE IN THE TREATMENT OF NEUROBLASTOMA, EWING'S SARCOMA OR RHABDOMYOSARCOMA | 06-02-2016 |
20160158211 | Dosage and Use of an A2A Antagonist - The present invention relates to specific dosages of an A | 06-09-2016 |
20160194312 | ACTIVATION OF TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND CRITICAL ROLE FOR TRPV4 IN ORGAN-SPECIFIC INFLAMMATION AND ITCH | 07-07-2016 |
20160199363 | TRPA1 AND TRPV4 INHIBITORS AND METHODS OF USING THE SAME FOR ORGAN-SPECIFIC INFLAMMATION AND ITCH | 07-14-2016 |
20160199364 | SEIZURE TREATMENT COMPOSITIONS AND METHODS | 07-14-2016 |
20180021320 | Method of Preventing or Treating Hearing Loss | 01-25-2018 |
20180022740 | ACTIVATION OF TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND CRITICAL ROLE FOR TRPV4 IN ORGAN-SPECIFIC INFLAMMATION AND ITCH | 01-25-2018 |